What is the Theratechnologies Inc. stock price forecast?

Theratechnologies Inc. is currently trading at $3.39. View real-time AI analysis on Alpha Lenz.

What is Theratechnologies Inc. insider trading activity?

View the latest insider trading data for Theratechnologies Inc. on Alpha Lenz.

What is Theratechnologies Inc.'s P/E ratio?

Theratechnologies Inc.'s P/E ratio is -20.1.

Theratechnologies Inc.

NASDAQ · THTX

$3.39

Ask about Theratechnologies Inc.'s future dividend policy...

Alpha Chat Insight

“Theratechnologies Inc. trades at a P/E of -20.1 (undervalued) with strong ROE of 36.0%.”

Ask for details →

Company Overview

Theratechnologies Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies. Specializing in niche markets, the company primarily targets unmet medical needs within the fields of endocrinology and oncology. Theratechnologies has a prominent role in the creation of solutions for HIV-associated lipodystrophy through its flagship product, Egrifta SV, which assists in reducing excess abdominal fat in HIV-infected patients. Additionally, Trogarzo, another critical product, is designed to offer treatment for multidrug-resistant HIV-1 in specific adult populations. These products underline Theratechnologies' commitment to advancing specialty care in life-altering diseases. Operating primarily in North American and European markets, Theratechnologies leverages its expertise in peptide technology and biologics to expand its therapeutic portfolio. The company is dedicated to addressing complex health issues, enhancing quality of life for patients, and holding a unique position in the pharmaceutical and health sectors. Its continued research and development efforts signify its impactful role in transforming patient care and pioneering in biotechnological advancements.

CEOMr. Paul Lévesque

Websitehttps://www.theratech.com

SectorHealthcare

IndustryBiotechnology

Employees103

Company Statistics

FY 2024

Profile

$167.34MMarket Cap

$85.87MRevenue

0.00Shares Out

103Employees

Margins

76.19%Gross

14.34%EBITDA

9.52%Operating

-7.34%Pre-Tax

-9.67%Net

Valuation

-20.15P/E

-6.62P/B

1.95EV/Sales

16.81EV/EBITDA

190.37P/FCF

Growth (CAGR)

7.14%Rev 3Yr

6.32%Rev 5Yr

N/AOp Inc 3Yr

N/AOp Inc 5Yr

N/ANet Inc 3Yr

N/ANet Inc 5Yr

Returns

-12.67%ROA

36.00%ROE

6.28%ROIC

Financial Health

$5.90MCash & Cash Equivalents

$72.71MNet Debt

-311.06%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“Theratechnologies Inc. trades at a P/E of -20.1 (undervalued) with strong ROE of 36.0%.”

Ask for details →

Frequently Asked Questions

Theratechnologies Inc. (ticker: THTX) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 103 employees. Market cap is $167M.

The current price is $3.39 with a P/E ratio of -20.15x and P/B of -6.62x.

ROE is 36.00% and operating margin is 9.52%. Annual revenue is $86M.